Day One Biopharmaceuticals (DAWN)
(Delayed Data from NSDQ)
$16.01 USD
+0.31 (1.97%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $16.00 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DAWN 16.01 +0.31(1.97%)
Will DAWN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DAWN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DAWN
Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up
Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More
DAWN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Could Help Day One Biopharmaceuticals, Inc. (DAWN) Maintain Its Recent Price Strength
Wall Street Analysts Think Day One Biopharmaceuticals, Inc. (DAWN) Could Surge 85%: Read This Before Placing a Bet
Biotech ETF Tops in June: 5 Stocks That Outperform
Other News for DAWN
Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal
Insider Selling: Director Saira Ramasastry Sells Shares of Day One Biopharmaceuticals Inc (DAWN)
Piper Sandler Remains a Buy on Day One Biopharmaceuticals (DAWN)
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Day One Biopharmaceuticals (DAWN) and Halozyme (HALO)
3 Best Stocks to Buy Now, 6/18/2024, According to Top Analysts